TEL AVIV, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced the closing of its previously announced private placement of ordinary shares and warrants to purchase ordinary shares for aggregate gross proceeds of approximately $15.0 million, before deducting placement agent fees and other offering expenses. Citizens Capital Markets acted as lead ...

Financing Activities15,125,489-Net Change in Cash and Cash Equivalents3,370,543-Cash and Cash Equivalents – Beginning of Period3,924,908112Cash and Cash Equivalents – End of Period$7,295,451$112Supplemental Disclosures of Cash Flow Information and Non-cash Transactions:Interest Paid$14,460$-SOURCE Citius Oncology, Inc.## 21%[more press release views with Request a Demo]## Also from this source### Citius Oncology Expands International Distribution of LYMPHIRâ"¢ to European Union Through Exclusive Agreement w ...

Core Viewpoint - Helus Pharma is advancing its clinical programs with a strong financial position and is well-positioned for upcoming clinical milestones, particularly in the treatment of mental health disorders [2][3]. Financial Highlights - As of December 31, 2025, the company reported cash totaling US$195.1 million before adjustments for post-quarter events [7]. - The net loss for the quarter ended December 31, 2025, was US$42.7 million, compared to a net loss of US$7.5 million in the same period last year [16]. - Cash-based operating expenses for the quarter were US$36.7 million, up from US$20 million in the same period last year [16]. Business and Pipeline Highlights - The company is focused on a differentiated neuroscience portfolio, with ongoing clinical programs HLP003 in Phase 3 for major depressive disorder and HLP004 in Phase 2 for generalized anxiety disorder [3][8]. - Upcoming topline data readout from the Phase 2 study evaluating HLP004 in generalized anxiety disorder is expected in Q1 2026 [5]. - The HLP003 Phase 3 program continues with pivotal studies APPROACH™ and EMBRACE™, with topline data anticipated in Q4 2026 [9]. Leadership and Strategic Focus - A leadership transition has been completed with the appointment of Michael Cola as CEO, aimed at leading the company towards a potential first commercial product launch [8]. - The company has rebranded to "Helus Pharma" and is focusing on engineered serotonergic agonists designed for controlled pharmacokinetics and potential commercial scalability [8]. Intellectual Property and Market Position - Helus Pharma is expanding and defending its intellectual property portfolio, which supports multiple programs and provides protection for lead programs HLP003 and HLP004 until at least 2041 [8].

Moderna beat fourth-quarter revenue estimates on stronger-than-expected demand for its Covid vaccines https://t.co/UV6mlNmHmm ...

Core Insights - Moderna reported fourth-quarter revenue of $678 million, exceeding Wall Street estimates of $626.1 million, driven by better-than-expected sales of its COVID-19 vaccine in the U.S. [1] - The company is facing financial challenges as demand for COVID vaccines has declined significantly since the pandemic peak, prompting efforts to develop new products to sustain revenue and demonstrate the long-term viability of its mRNA technology [1] - Moderna reiterated its expectation of achieving 10% revenue growth by 2026 [1]

President Trump officially launched TrumpRx on February 5, touting it as a game-changer for prescription drug costs. The reality, however, is that health policy experts believe only a limited number of Americans will actually benefit from this plan, while millions could end up paying more without comparison shopping. Must Read According to a White House press release, the TrumpRx.gov website features at least 40 brand-name medications with discounted prices from five pharmaceutical companies (1). And w ...

Group 1 - ALK will publish its annual report for 2025 on February 20, 2026, and will host a presentation for investors and analysts later that day at 1:30 p.m. CET [1] - The presentation will be led by ALK's management team, including Peter Halling (President & CEO), Claus Steensen Sølje (CFO), and Per Plotnikof (VP, Head of IR) [1] - The meeting will be available as a live audio webcast and can be replayed on ALK's website [2] Group 2 - Participants can join the conference call by registering through a provided link, and they will receive dial-in details via email [3] - The presentation materials will be accessible on ALK's website shortly before the meeting begins [4] Group 3 - ALK is a global specialty pharmaceutical company focused on allergy, involved in the entire value chain from development to marketing of products for respiratory allergies and anaphylaxis [6] - The company is headquartered in Denmark, employs around 2,700 people, and is listed on Nasdaq Copenhagen [6]

Core Viewpoint - ALK will publish its annual report for 2025 on February 20, 2026, and will host a presentation for investors and analysts later that day to discuss results and outlook [1]. Group 1: Annual Report and Presentation - The annual report for 2025 will be released in the morning on February 20, 2026 [1]. - A presentation for investors and analysts will take place at 1:30 p.m. CET on the same day, featuring comments from ALK's management [1]. - Key representatives from ALK during the presentation will include Peter Halling (President & CEO), Claus Steensen Sølje (CFO), and Per Plotnikof (VP, Head of IR) [1]. Group 2: Participation and Access - The presentation will be available via live audio webcast and can be replayed on ALK's website [2]. - For those wishing to participate via telephone, registration is required, and details will be provided via email after registration [3]. - The presentation materials will be accessible on ALK's website shortly before the meeting starts [4]. Group 3: Company Overview - ALK is a global specialty pharmaceutical company focused on allergy, covering the entire value chain from development to marketing of products for diagnosing and treating respiratory allergies and anaphylaxis [6]. - The company is headquartered in Denmark and employs approximately 2,700 people worldwide, listed on Nasdaq Copenhagen [6].

Core Insights - The earnings season for Europe's largest pharmaceutical companies showed mixed results, but the focus is shifting towards future developments, particularly in 2026, which is expected to be a pivotal year following significant changes in 2025 [1][2] Industry Trends - Companies are facing a "patent cliff," where major drugs will lose exclusivity, leading to increased competition from generics [3] - There is a heightened emphasis on drug pipelines as companies aim to reassure investors about future growth despite impending patent expirations [4] Company Strategies - Novartis anticipates a loss of $4 billion in sales and profits in the first half of the year due to patent expirations but remains optimistic about growth driven by a strong pipeline [5] - AstraZeneca is confident in its pipeline, projecting 25 new blockbuster medicines by 2030 and aiming for $80 billion in revenue, up from $59 billion in 2025 [8] - Companies are increasingly looking towards mergers and acquisitions (M&A) to replenish their pipelines, with a focus on both smaller and larger deals [9][11] Market Dynamics - China is emerging as a significant source of innovation for pharmaceutical companies, with increased collaboration and deal-making with Chinese firms [13][15] - The market is evolving in terms of pricing strategies, particularly in response to U.S. and European pricing pressures, with companies considering various approaches to manage drug launches [16][17] Obesity Drug Market - The obesity drug market is becoming more consumer-oriented, with companies like Novo Nordisk and Eli Lilly facing increasing competition as new players enter the space [20] - AstraZeneca and Roche are developing new treatments to differentiate themselves in the crowded obesity market, focusing on convenience and improved tolerability profiles [21][23][24]

Core Viewpoint - The Trump administration may take legal action against Hims for attempting to sell a compounded version of Novo Nordisk's Wegovy weight-loss pill, following the FDA's referral to the DOJ for potential violations of federal law [1]. Group 1: Legal Actions and Implications - Hims initially planned to offer a $49 version of Wegovy but backed off after the FDA's warning [1]. - The DOJ could pursue an injunction or fines against Hims for marketing an unapproved drug, as indicated by legal experts [1]. - The FDA's actions aim to protect pharmaceutical investments and ensure product safety, highlighting concerns over compounded drugs that have not undergone rigorous testing [1]. Group 2: Industry Context and Reactions - Weight-loss drug manufacturers, including Novo Nordisk and Eli Lilly, are struggling to meet the increasing demand for their products [1]. - Compounded pharmaceuticals are legal under specific conditions, but the FDA can enforce actions against those that bypass the federal approval process [1]. - Hims claims its products are legal due to patient personalization, but the legality of this claim is under scrutiny [1]. Group 3: Future Considerations - The FDA may inspect Hims' records to assess compliance with prescription documentation [1]. - Hims' withdrawal from offering the compounded weight-loss pill may influence the DOJ's decision on whether to take action [1]. - The administration could focus on Hims' compounded injectable weight-loss drugs, which present a more complex legal case [1].